Literature DB >> 23430399

A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.

Masato Fujii1, Yuichiro Shibazaki, Kyoko Wakamatsu, Yutaka Honda, Yusuke Kawauchi, Kenji Suzuki, Somasundaram Arumugam, Kenichi Watanabe, Takafumi Ichida, Hitoshi Asakura, Hiroyuki Yoneyama.   

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths. In addition to hepatitis viral infections, several cohort studies have shown that diabetes mellitus is a risk factor of HCC, making the incidence alarming high. However, it has not been demonstrated directly how diabetes develops to HCC, because of its difficulty to follow changes of liver histology in diabetic populations. Here, we report that non-alcoholic steatohepatitis (NASH) is pivotal to link diabetes with HCC by establishing a novel, reproducible NASH-HCC model in mice. Neonatal male mice exposed to low-dose streptozotocin (STZ) developed liver steatosis with diabetes 1 week after feeding high-fat diet (HFD). Continuous HFD decreased hepatic fat deposit whilst increased lobular inflammation with foam cell-like macrophages, showing NASH pathology. In parallel with decreased phagocytosis of macrophages, fibroblasts accumulated to form "chicken-wired" fibrosis. All mice developed multiple HCC later. Female mice treated with STZ-HFD and male mice treated with STZ alone showed diabetes but never developed HCC by the absence of NASH-based fibrosis. Thus, the present study provides the evidence in novel mouse model that NASH-based fibrosis is an essential histological process for diabetic populations to accelerate the development of HCC.

Entities:  

Mesh:

Year:  2013        PMID: 23430399     DOI: 10.1007/s00795-013-0016-1

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  41 in total

1.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

2.  Tamoxifen-induced fatty liver in patients with breast cancer.

Authors:  Y Ogawa; Y Murata; A Nishioka; T Inomata; S Yoshida
Journal:  Lancet       Date:  1998-03-07       Impact factor: 79.321

Review 3.  The changing pattern of epidemiology in hepatocellular carcinoma.

Authors:  Helena Nordenstedt; Donna L White; Hashem B El-Serag
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

Review 4.  Mouse models in liver cancer research: a review of current literature.

Authors:  Martijn W H Leenders; Maarten W Nijkamp; Inne H M Borel Rinkes
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

5.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

6.  Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice.

Authors:  H Yoneyama; A Harada; T Imai; M Baba; O Yoshie; Y Zhang; H Higashi; M Murai; H Asakura; K Matsushima
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

7.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

Review 8.  Rapid regression of atherosclerosis: insights from the clinical and experimental literature.

Authors:  Kevin Jon Williams; Jonathan E Feig; Edward A Fisher
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-02

Review 9.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.

Authors:  Catherine Postic; Jean Girard
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

Review 10.  Animal models of NASH: getting both pathology and metabolic context right.

Authors:  Claire Z Larter; Matthew M Yeh
Journal:  J Gastroenterol Hepatol       Date:  2008-08-21       Impact factor: 4.029

View more
  117 in total

1.  Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer.

Authors:  Joan Font-Burgada; Shabnam Shalapour; Suvasini Ramaswamy; Brian Hsueh; David Rossell; Atsushi Umemura; Koji Taniguchi; Hayato Nakagawa; Mark A Valasek; Li Ye; Janel L Kopp; Maike Sander; Hannah Carter; Karl Deisseroth; Inder M Verma; Michael Karin
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

2.  Mouse Models of Liver Fibrosis.

Authors:  Aashreya Ravichandra; Robert F Schwabe
Journal:  Methods Mol Biol       Date:  2021

3.  Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation.

Authors:  Tetsuyuki Takahashi; Ulrich Deuschle; Shu Taira; Takeshi Nishida; Makoto Fujimoto; Takao Hijikata; Koichi Tsuneyama
Journal:  Hepatol Int       Date:  2018-04-12       Impact factor: 6.047

4.  Immunomodulatory spherical nucleic acids.

Authors:  Aleksandar F Radovic-Moreno; Natalia Chernyak; Christopher C Mader; Subbarao Nallagatla; Richard S Kang; Liangliang Hao; David A Walker; Tiffany L Halo; Timothy J Merkel; Clayton H Rische; Sagar Anantatmula; Merideth Burkhart; Chad A Mirkin; Sergei M Gryaznov
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

5.  Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM mice.

Authors:  Yasunobu Yoshida; Jun-Ichi Furukawa; Shoichi Naito; Kenichi Higashino; Yoshito Numata; Yasuro Shinohara
Journal:  Glycoconj J       Date:  2018-09-08       Impact factor: 2.916

6.  Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis.

Authors:  Guoxiang Xie; Xiaoning Wang; Fengjie Huang; Aihua Zhao; Wenlian Chen; Jingyu Yan; Yunjing Zhang; Sha Lei; Kun Ge; Xiaojiao Zheng; Jiajian Liu; Mingming Su; Ping Liu; Wei Jia
Journal:  Int J Cancer       Date:  2016-06-17       Impact factor: 7.396

7.  Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.

Authors:  Thomas Klein; Masato Fujii; Jan Sandel; Yuichiro Shibazaki; Kyoko Wakamatsu; Michael Mark; Hiroyuki Yoneyama
Journal:  Med Mol Morphol       Date:  2013-09-19       Impact factor: 2.309

8.  A Mitochondrial VDAC1-Based Peptide Greatly Suppresses Steatosis and NASH-Associated Pathologies in a Mouse Model.

Authors:  Srinivas Pittala; Yakov Krelin; Yael Kuperman; Varda Shoshan-Barmatz
Journal:  Mol Ther       Date:  2019-07-12       Impact factor: 11.454

9.  Integrative genomic analysis of mouse and human hepatocellular carcinoma.

Authors:  Michelle Dow; Rachel M Pyke; Brian Y Tsui; Ludmil B Alexandrov; Hayato Nakagawa; Koji Taniguchi; Ekihiro Seki; Olivier Harismendy; Shabnam Shalapour; Michael Karin; Hannah Carter; Joan Font-Burgada
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-04       Impact factor: 11.205

Review 10.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.